Status:

COMPLETED

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)

Lead Sponsor:

Merck Sharp & Dohme LLC

Conditions:

Nausea

Vomiting

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

A multicenter trial to assess the safety and efficacy of an investigational drug in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with confirmed solid tumors who will b...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Patient is greater than 18 years of age.
  • Patient is scheduled to receive his/her first
  • course of cisplatin chemotherapy for a solid tumor.
  • Patient has a prognosis (life expectancy) greater than or equal to 3 months.

Exclusion

    Key Trial Info

    Start Date :

    January 13 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    September 30 2004

    Estimated Enrollment :

    477 Patients enrolled

    Trial Details

    Trial ID

    NCT00090207

    Start Date

    January 13 2004

    End Date

    September 30 2004

    Last Update

    April 24 2017

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

    Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED) | DecenTrialz